Bruker Daltonik GmbH and VWR International Announce European Co-Marketing Agreement For LC/MS Systems.Business Editors/Health/Medical Writers BREMEN, Germany & BRUSSELS, Belgium--(BUSINESS WIRE)--May 11, 2004 Bruker Daltonik GmbH, a subsidiary of Bruker BioSciences Corporation Bruker Biosciences Corporation is a Massachusetts-based company formed in 2003 which develops and manufactures scientific instrumentation for academic research and industrial use. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BRKR BRKR Breaker ), and VWR International Europe BVBA's Scientific Instruments business unit today announce a co-marketing agreement to jointly market certain VWR VWR Van Waters and Rogers VWR Viewer File HPLC HPLC high-performance liquid chromatography. HPLC high performance liquid chromatography. HPLC High-performance liquid chromatography Lab instrumentation A highly sensitive analytic method in which analytes are placed and Bruker Daltonik bench-top mass spectrometers, including software, via their respective distribution channels in Europe. VWR International will market the Bruker Daltonik esquire4000(TM) LC/MS/MS ion trap mass spectrometer in Europe in combination with its LaChrom Elite(TM) HPLC system. At the same time, Bruker Daltonik will offer the LaChrom Elite in combination with its range of bench-top LC/MS LC/MS Liquid Chromatography/Mass Spectrometry Ion Trap and Time-Of-Flight systems. Using one integrated software platform, the Bruker Daltonik COMPASS(TM) LC/MS software suite will control both the LaChrom Elite HPLC system and the mass spectrometer detector. The combination of both parties' products with their renowned quality and high performance offers powerful LC/MS solutions to customers in the life and chemical sciences. Bruker Daltonik GmbH's Managing Director, Hans Baum, said: "We are delighted to establish this strong distribution relationship with VWR International. We look forward to providing highly productive bench-top LC/MS systems with accurate mass and MS/MS MS/MS Tandem Mass Spectroscopy MS/MS Multistage Mass Spectrometry capabilities to customers in the pharmaceutical, biotech and other industries. With our new unified software environment, COMPASS, the entire LC/MS workflow can be fully automated with a simple method-driven approach." Patrick Surkyn, Business Director VWR Scientific Instruments, stated: "The strategic relationship with Bruker Daltonik fits perfectly in VWR's partner-strategy and will provide our customers with a complete range of products and services for the HPLC laboratory: Analytical and preparative pre·par·a·tive adj. Serving or tending to prepare or make ready; preliminary. n. Something that prepares for or acts as a preliminary to something following. systems, chromatography data systems (PC workstations as well as network versions), technical, quality and software services, and now also LC-MS systems." About VWR International VWR International is a global leader in the distribution of scientific supplies, with worldwide sales of $2.8 billion. VWR's business is highly diversified across a spectrum of products and services, customer groups and geography. VWR International affiliates operate in 18 countries and employ about 6,000 people. For further information, please see http://www.vwr.com/. About Bruker BioSciences Bruker BioSciences, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker Daltonics Inc. and Bruker AXS Inc. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. Bruker AXS is a leading developer and provider of life science and advanced materials research tools based on X-ray technology. For more information about Bruker BioSciences Corporation, please visit www.bruker-biosciences.com. CAUTIONARY STATEMENT OF BRUKER BIOSCIENCES Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company's products, changes in governmental regulations, capital spending and government funding policies, FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. . These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K for the year ended December 31, 2003, our most recent quarterly reports on Form 10-Q, our current reports on Form 8-K . We disclaim any intent or obligation to update these forward-looking statements. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion